IMVT

Immunovant has delivered a striking 5 year return, yet the recent pullback and legal questions around its governance put fresh focus on whether the current share price still lines up with what its balance sheet supports.

Immunovant is developing IMVT-1402 in an ongoing mid-stage study in Sjögren’s disease, which works the same way as Argenx’s efgartigimod.

Immunovant recently reported topline results from Period 1 of its proof-of-concept trial of IMVT-1402 in cutaneous lupus erythematosus, where the drug did not achieve statistical significance on the primary CLASI-A endpoint at Week 12, leading the company to halt development for this indication.

Immunovant (IMVT) just told the market that its proof-of-concept Phase 2b trial for IMVT-1402 in cutaneous lupus erythematosus missed the primary efficacy goal, and the program in this indication is being discontinued.

We all have bad days. Immunovant, Inc. (NASDAQ:IMVT) had its latest bad day on September 23 after a clinical-trial setback, sending the shares lower.

Immunovant stock fell roughly 6% to a more-than-three-month low on September 23, 2026 after the IMVT-1402 cutaneous lupus study missed its primary endpoint.

Immunovant's IMVT-1402 misses its primary CLE goal, prompting the company to halt the program despite positive trends and a favorable safety profile.

Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.

This study enrolled 57 adult patients with CLE, who were assigned to receive either IMVT-1402 or a placebo.

Immunovant halts development of its lead drug candidate, imeroprubart, in skin lupus following a trial miss.